CD274 and neoplasm: The cost-effectiveness analyses were conducted, respectively, in three populations with different PD-L1 expression levels (≥50, ≥1, and <1%) or patients with a high tumor mutational burden (TMB) (≥10 mutations per megabase), using the most recently reported data from CheckMate 227 (17–19).